{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=82",
    "query": {
      "intervention": "Placebo,",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 33205,
    "total_pages": 3321,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:20:30.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03489226",
      "title": "Capsimax Effect on Metabolic Rate, Satiety and Food Intake",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Energy Metabolism",
        "Eating",
        "Hunger"
      ],
      "interventions": [
        {
          "name": "Capsimax",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Meal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-05-02",
      "completion_date": "2017-07-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03489226"
    },
    {
      "nct_id": "NCT04138615",
      "title": "Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Morphine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 44,
      "start_date": "2019-11-12",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2023-01-12",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04138615"
    },
    {
      "nct_id": "NCT02790125",
      "title": "A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BMS-986166",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BMS-986166",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-07-28",
      "completion_date": "2017-11-07",
      "has_results": false,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02790125"
    },
    {
      "nct_id": "NCT01573468",
      "title": "Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tesetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genta Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2012-04",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2012-07-24",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01573468"
    },
    {
      "nct_id": "NCT00584168",
      "title": "Using Dexamethasone After Uvulopalatopharyngoplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2005-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-02",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584168"
    },
    {
      "nct_id": "NCT02257489",
      "title": "Phase 1 Study of ACE-083 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Musculoskeletal Diseases"
      ],
      "interventions": [
        {
          "name": "ACE-083",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 75 Years · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2014-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257489"
    },
    {
      "nct_id": "NCT03271489",
      "title": "Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Uterine Fibroids"
      ],
      "interventions": [
        {
          "name": "Elagolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol /norethindrone acetate (E2/NETA)",
          "type": "DRUG"
        },
        {
          "name": "E2/NETA Placebo",
          "type": "OTHER"
        },
        {
          "name": "Elagolix Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 478,
      "start_date": "2017-09-13",
      "completion_date": "2024-06-28",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 155,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03271489"
    },
    {
      "nct_id": "NCT04003389",
      "title": "A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "fezolinetant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 1831,
      "start_date": "2019-07-10",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-05",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 142,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Ensley",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003389"
    },
    {
      "nct_id": "NCT01367990",
      "title": "Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alopecia",
        "Radiodermatitis"
      ],
      "interventions": [
        {
          "name": "Norepinephrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ProCertus BioPharm, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2011-07",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01367990"
    },
    {
      "nct_id": "NCT02227290",
      "title": "Pediatric Subjects With Tinea Corporis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tinea Corporis"
      ],
      "interventions": [
        {
          "name": "Naftin Cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz North America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 230,
      "start_date": "2014-08",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-10-28",
      "last_synced_at": "2026-11-19T04:20:30.285Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Encino, California • Fremont, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227290"
    }
  ]
}